Since its entry into routine use, prostate-specific antigen (PSA) has been considered an ideal indicator of bone metastasis in patients with prostate cancer, with a serum PSA value of >100 ng/mL signifying a greater likelihood of existing bone metastases at first diagnosis [65]. This evidence concerns the gene KLK3 and prostate carcinoma.